Zobrazeno 1 - 10
of 846
pro vyhledávání: ''
Autor:
Gregor Lindner, Svenja Ravioli, Shawki Bahmad, Aristomenis K. Exadaktylos, Christoph Schwarz, Georg-Christian Funk
Publikováno v:
The American Journal of Medicine. 134:1148-1154
Background: Thiazide diuretics are a mainstay in the management of hypertension and often associated with dyselectrolytemias. We investigated the prevalence of and risk factors for hyponatremia and hypokalemia in thiazide users, substance-specific di
Publikováno v:
The American Journal of Medicine. 134:926-929
Background Intrathoracic involvement with lymphomas is common and manifests lymphadenopathy as well as a wide spectrum of imaging abnormalities in the lungs. Intravascular large B-cell lymphoma (IVLBCL) is a rare extranodal subtype of large B-cell ly
Autor:
Pradyumna Agasthi, Nirat Beohar, David R. Holmes, Mohamed Allam, Pattara Rattanawong, Sai Harika Pujari, Komandoor Srivathsan, Dan Sorajja, Win Kuang Shen, William K. Freeman, Ramila A. Mehta, Hicham El Masry, Farouk Mookadam, Eric H. Yang, Hasan Ashraf, Xiaoxi Yao, Anusha Shanbhag, Reza Arsanjani, Siva K. Mulpuru, Peter A. Noseworthy
Publikováno v:
The American Journal of Medicine. 134:788-796
Background Although direct oral anticoagulants (DOACs) have been shown to be effective at reducing the risk of stroke in patients with atrial fibrillation/flutter (AF), they are sometimes underdosed off-label to mitigate their associated higher bleed
Publikováno v:
The American Journal of Medicine. 134:477-481
Autor:
Charity J. Morgan, Hans Moore, Markus S. Anker, Cherinne Arundel, Prakash Deedwania, Richard M. Allman, Samuel Wopperer, Steven N. Singh, Charles Faselis, Gregg C. Fonarow, Qing Zeng, Phillip H. Lam, Lakshmi Tummala, Pamela Karasik, Ali Ahmed
Publikováno v:
The American Journal of Medicine. 133:1460-1470
Background Digoxin reduces the risk of heart failure hospitalization but has no effect on mortality in patients with heart failure without atrial fibrillation in the randomized controlled trial setting. Observational studies of digoxin use in patient
Publikováno v:
The American Journal of Medicine. 133:1209-1218
Background Chronic opioid use and dependence is common in patients with chronic pancreatitis. Patients with acute pancreatitis are frequently treated with opioids, but their risk for ongoing use is not well known. The aim of our study is to character
Autor:
Cherinne Arundel, Milton Packer, Steven N. Singh, Yan Cheng, Wayne C. Levy, Richard M. Allman, Vijaywant Brar, Wen-Chih Wu, Gregg C. Fonarow, Phillip H. Lam, Michael R. Zile, Ali Ahmed, Gauravpal S. Gill
Publikováno v:
The American Journal of Medicine. 133:1187-1194
Background Digoxin reduces the risk of heart failure hospitalization in patients with heart failure with reduced ejection fraction. Less is known about this association in patients with heart failure with preserved ejection fraction (HFpEF), the exam
Autor:
Emmanuel Achu, Marc Goldschmidt, Joseph S. Alpert, James Cassuto, M.J. Zucker, David A. Baran, Ahmed Harhash, Ahmed Hussein
Publikováno v:
The American Journal of Medicine. 133:857-864
Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation. M
Autor:
Harlan M. Krumholz, Isuru Ranasinghe, Suveen Angraal, Nihar R. Desai, Nilay Shah, James V. Freeman, Karthik Murugiah, Yun Wang, Frederick A. Masoudi, Sudhakar V. Nuti
Publikováno v:
The American Journal of Medicine. 132:1191-1198
Background Over the past 2 decades, guidelines for digoxin use have changed significantly. However, little is known about the national-level trends of digoxin use, hospitalizations for toxicity, and subsequent outcomes over this time period. Methods
Autor:
Thomas J. Bunz, Daniel Eriksson, Reinhold Kreutz, Nitesh Sood, Anna-Katharina Meinecke, Craig I Coleman, William L. Baker
Publikováno v:
The American Journal of Medicine. 132:1078-1083
Patients with nonvalvular atrial fibrillation with stage 4 or 5 chronic kidney disease or undergoing hemodialysis were excluded from phase III randomized trials of nonvitamin K antagonist oral anticoagulants (NOACs). We sought to evaluate the effecti